French study tracks promising leukemia drug available through special access

NCT ID NCT06377579

Summary

This study is observing how well the drug Ivosidenib works and how safe it is for adults with a specific genetic type of acute myeloid leukemia (AML) in France. It will look back at the medical records of about 250 patients who received the drug through a special access program, either as a first treatment or after their cancer returned. The goal is to gather real-world evidence on survival and side effects to support future approval of the drug in Europe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amiens CHU

    NOT_YET_RECRUITING

    Amiens, France

    Contact Email: •••••@•••••

  • Angers CHU

    NOT_YET_RECRUITING

    Angers, France

    Contact Email: •••••@•••••

  • Bayonne CH

    NOT_YET_RECRUITING

    Bayonne, France

    Contact Email: •••••@•••••

  • Besançon CHU

    NOT_YET_RECRUITING

    Besançon, France

    Contact Email: •••••@•••••

  • Bordeaux CHU

    NOT_YET_RECRUITING

    Pessac, France

    Contact Email: •••••@•••••

  • CHU Estaing

    RECRUITING

    Clermont-Ferrand, France

    Contact Email: •••••@•••••

  • Créteil CHU HENRI MONDOR

    RECRUITING

    Créteil, France

    Contact Email: •••••@•••••

  • DUNKERQUE-Hôpital Alexandra Lepève

    RECRUITING

    Dunkirk, 59385, France

    Contact Email: •••••@•••••

    Contact

  • Grenoble CHU

    NOT_YET_RECRUITING

    Grenoble, France

    Contact Email: •••••@•••••

  • ICANS - Institut de cancérologie de strasbourg europe

    NOT_YET_RECRUITING

    Strasbourg, France

    Contact Email: •••••@•••••

  • Le Mans CH

    NOT_YET_RECRUITING

    Le Mans, France

    Contact Email: •••••@•••••

  • Lyon sud CHU

    NOT_YET_RECRUITING

    Lyon, France

    Contact Email: •••••@•••••

  • Marseille IPC

    NOT_YET_RECRUITING

    Marseille, France

    Contact Email: •••••@•••••

  • Meaux CH de l'Est francilien

    RECRUITING

    Meaux, France

    Contact Email: •••••@•••••

  • Montpellier - Chu Saint Eloi

    NOT_YET_RECRUITING

    Montpellier, France

    Contact Email: •••••@•••••

  • Mulhouse Chu

    RECRUITING

    Mulhouse, 68100, France

    Contact

    Contact Email: •••••@•••••

  • Nantes CHU

    RECRUITING

    Nantes, France

    Contact Email: •••••@•••••

  • Nice CHU

    NOT_YET_RECRUITING

    Nice, France

    Contact Email: •••••@•••••

  • Orléans CHU

    NOT_YET_RECRUITING

    Orléans, 45000, France

    Contact Email: •••••@•••••

    Contact

  • Paris Saint Louis

    NOT_YET_RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Toulouse - IUCT Oncopole - Service d'Hématologie

    NOT_YET_RECRUITING

    Toulouse, France

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.